跳至主要内容
临床试验/NCT02078869
NCT02078869已完成不适用

Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial

Toronto Centre for Advanced Reproductive Technology0 个研究点目标入组 34 人开始时间: 2015年5月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
34
主要终点
Number of Uterine Endometrial Contractions Per Minute

研究概览

简要总结

When patients undergo in vitro fertilization (IVF), they often make more embryos than it is safe to transfer back in the womb all at once. These excess embryos are frozen and stored for future use. Frozen embryo transfer (FET) is therefore an important option of IVF where there are extra embryos. FET should take place under ideal conditions when uterine receptivity and uterine endometrial lining thickness are at the appropriate developmental stage as the embryo. A common way of preparing the uterus for FET is by using medications (Estrogen and Progesterone) that imitate a normal menstrual cycle while monitoring the endometrial lining development by transvaginal ultrasound. Progesterone (P4) may be administered vaginally or intra-muscularly (IM). The mode of Progesterone administration is based upon local conventions, experts' opinion and patients' preferences. All the mentioned modalities are common in the daily practice of IVF clinics across the world.

The current medical literature does not present high quality evidence for the superiority of one form of Progesterone administration over the other for FET. The investigators know that in fresh embryo transfer cycles where natural follicles continue to function and produce Progesterone as corpora lutea, there were no reported differences in pregnancy rates when luteal vaginal P4 was compared with IM P4 support, but the investigators do not have the same reassurance regarding frozen embryo transfers. The aim of this study is to compare vaginal versus IM route of administration of P4 for FET cycle in a well-designed trial. Since many outcome variables are possible, the investigators have chosen to concentrate in the one that might shed light on a possible biological difference between the two modes of Progesterone administration; uterine contractions. Uterine contractions have been previously recognized as a possible factor that compromises success rates in patients undergoing IVF treatments. Progesterone is considered a uterine relaxant and its levels in the blood versus the levels in the uterus differ by its mode of administration: blood levels are higher when given IM whereas uterine P4 concentrations are higher when given vaginally. The investigators are interested to see whether IM progesterone in frozen embryo transfers presents a different uterine contraction pattern than the vaginal administration.

详细描述

This is a randomized un-blinded clinical trial for comparing uterine contractions frequency in FET cycles between two medicated protocols of uterine lining programming. This study does not involve any new medications, nor mode of administration, but merely a designed array for evaluation of two existing well-established protocols.

Women undergoing Frozen embryo transfers (FET) at the blastocyst stage at the Toronto Centre for Advanced Reproductive Technologies (TCART) will be approached to take part in this study.

Pre-study Screening and Baseline Evaluation:

Study subjects will be recruited voluntarily at TCART clinic. The attending physician will screen and identify potential female patients undergoing in vitro fertilization (IVF) blastocyst FET cycles. The staff physician will explain the general rational. The protocol of the study and further explanations as well as the actual recruitment will be performed by a nurse or a fellow who are not part of the treating team. If the patient gives her consent, she will be randomized (computer generated block randomization) into one of the treatment groups (vaginal P4 or IM P4).

FET medicated cycle protocol includes ten days of Estrace (micronized 17b-estradiol) starting on day 3 of the cycle at a dose of 4 mg daily for 5 days followed by 8 mg daily for 5 days. Routine monitoring takes place after the 10th treatment day - cycle day 13 - and involves a longitudinal scan of the uterine cavity for endometrial thickness and pattern. This is not a study visit but a routine one that is part of the investigators standard of care. The study patients' monitoring will include one additional measurement (uterine contraction frequency counted by number of contractions per minute). After achieving sufficient endometrial proliferation (≥7 mm thickness with a triple layer pattern) with estrogen exposure, the patient starts progesterone use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 43 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients in the reproductive age group (18-43 years) undergoing IVF FET cycle, blastocyst stage.

排除标准

  • History of reaction to either one of the P4 medication
  • Current use of calcium channels blockers
  • Uterine factor infertility
  • Acupuncture therapy during current cycle

研究组 & 干预措施

intramuscular Progesterone in oil

Active Comparator

50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer

干预措施: Progesterone in oil (Drug)

vaginal progesterone suppositories

Active Comparator

200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer

干预措施: vaginal progesterone suppositories (Drug)

结局指标

主要结局

Number of Uterine Endometrial Contractions Per Minute

时间窗: on the day of frozen embryo transfer

The primary outcome will be the number of contractions per minute assessed over 5 minutes on the day of FET.

次要结局

  • Implantation Rate(The outcome of the study cycle- tested 4 weeks after the transfer)

研究者

发起方
Toronto Centre for Advanced Reproductive Technology
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Robert F. Casper

Professor (University of Toronto)

Toronto Centre for Advanced Reproductive Technology

相似试验